Merck & Co., Inc. (MRK) – KEYTRUDA continues to drive growth

Merck & Co., Inc. (MRK) (Q2FY23)

Introduction

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health.

The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines.

The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products.

The company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. It has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics LP; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. 

Highlights

In the latest report, Animal Health sales demonstrated a 2% increase, reaching a total of $1.5bn. The 2% growth in the livestock sector can be attributed to a combination of price adjustments and increased demand for swine and poultry products.

Stock performance

Merck & Co stock price showed a volatile trend in past 3-months. It declined by 0.18% during the period. The stock price increased by 29.11% in past 1-year. The stock has a 52-week high of $119.65 and its 52-week low is $84.52.

In the past 3 years, the stock has given 35.55% returns. MRK has a 50-day moving Avg. and 200-day moving Avg. of $108.97 and $109.75, respectively.

This report is useful for M&A, business & investment analysis to all students, researchers, investors, private equity houses, broking firms, hedge funds, advisory firms and corporates to decide upon their investment strategies. Do connect with us, if you are looking for equity valuation, recommendation, analysis and market recommendation for any specific company, sector and industry.

Highlights

Valuation

– Enterprise Value
– CrispIdea Forecast
– Economic Value Added Analysis
– DCF Analysis
– P/E Analysis
– Peer Valuation
– CrispIdea Forecast Relative to Consensus
– Consensus History and Surprise
– Consensus Momentum

Actual & Historical Performance

– Income Statement
– Balance Sheet
– Cash Flow
– 10 Year Historical Performance
– Ratio Analysis
– Du Pont Analysis
– ROIC & ROCE Analysis
– Segment Performance
– Key Developments
– M&A Deals

Peer Performance

– Summary
– Profitability
– Growth
– Price Performance

Ownership

Stock Price Performance

CrispIdea Coverage

No of Pages: 37

To download the previous quarter’s equity report CLICK HERE

To Download other equity/ stock reports CLICK HERE

Follow our LinkedIn page for more updates.